Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 9 studies | 25% ± 5% | |
| epithelial cell | 6 studies | 31% ± 14% | |
| fibroblast | 6 studies | 18% ± 2% | |
| ciliated cell | 5 studies | 25% ± 8% | |
| neuron | 4 studies | 23% ± 7% | |
| basal cell | 4 studies | 24% ± 4% | |
| GABAergic neuron | 4 studies | 38% ± 13% | |
| astrocyte | 4 studies | 31% ± 7% | |
| macrophage | 4 studies | 21% ± 2% | |
| classical monocyte | 3 studies | 33% ± 4% | |
| abnormal cell | 3 studies | 20% ± 6% | |
| glutamatergic neuron | 3 studies | 59% ± 7% | |
| oligodendrocyte precursor cell | 3 studies | 26% ± 4% | |
| endothelial cell of lymphatic vessel | 3 studies | 18% ± 1% | |
| oligodendrocyte | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| bladder | 100% | 8275.76 | 21 / 21 | 100% | 40.70 | 504 / 504 |
| esophagus | 100% | 8190.22 | 1445 / 1445 | 100% | 44.78 | 183 / 183 |
| lung | 100% | 10712.35 | 578 / 578 | 100% | 39.78 | 1155 / 1155 |
| stomach | 100% | 6879.35 | 359 / 359 | 100% | 38.94 | 286 / 286 |
| breast | 100% | 8978.01 | 459 / 459 | 100% | 73.26 | 1117 / 1118 |
| intestine | 100% | 9464.04 | 966 / 966 | 100% | 39.48 | 526 / 527 |
| prostate | 100% | 9603.31 | 245 / 245 | 100% | 46.50 | 501 / 502 |
| ovary | 100% | 9659.10 | 180 / 180 | 100% | 28.72 | 429 / 430 |
| pancreas | 100% | 4914.79 | 328 / 328 | 99% | 39.78 | 177 / 178 |
| brain | 99% | 7215.75 | 2627 / 2642 | 100% | 54.66 | 705 / 705 |
| uterus | 100% | 12871.64 | 170 / 170 | 99% | 44.62 | 456 / 459 |
| thymus | 100% | 11382.84 | 653 / 653 | 99% | 35.34 | 600 / 605 |
| skin | 100% | 8757.50 | 1809 / 1809 | 99% | 37.38 | 467 / 472 |
| kidney | 100% | 7050.30 | 89 / 89 | 97% | 24.64 | 877 / 901 |
| adrenal gland | 100% | 6985.03 | 258 / 258 | 96% | 29.04 | 221 / 230 |
| liver | 100% | 3813.98 | 225 / 226 | 96% | 21.49 | 389 / 406 |
| adipose | 100% | 8758.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 29.55 | 29 / 29 |
| muscle | 100% | 6343.84 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 13568.84 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 35.50 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 25.60 | 1 / 1 |
| blood vessel | 100% | 9014.34 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 4562.77 | 856 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 13971.37 | 918 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 94% | 24.67 | 75 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0016607 | Cellular component | nuclear speck |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0072487 | Cellular component | MSL complex |
| GO_0005634 | Cellular component | nucleus |
| GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0003682 | Molecular function | chromatin binding |
| Gene name | MSL1 |
| Protein name | Male-specific lethal 1 homolog (MSL-1) (Male-specific lethal 1-like 1) (MSL1-like 1) (Male-specific lethal-1 homolog 1) MSL complex subunit 1 |
| Synonyms | MSL1L1 |
| Description | FUNCTION: Component of histone acetyltransferase complex responsible for the majority of histone H4 acetylation at 'Lys-16' (H4K16ac) which is implicated in the formation of higher-order chromatin structure . Greatly enhances MSL2 E3 ubiquitin ligase activity, promoting monoubiquitination of histone H2B at 'Lys-34' (H2BK34Ub) . This modification in turn stimulates histone H3 methylation at 'Lys-4' (H3K4me) and 'Lys-79' (H3K79me) and leads to gene activation, including that of HOXA9 and MEIS1 . In the MSL complex, acts as a scaffold to tether MSL3 and KAT8 together for enzymatic activity regulation . . |
| Accessions | ENST00000398532.9 [Q68DK7-1] J3KRQ4 ENST00000582884.5 J3QQY0 ENST00000582920.1 ENST00000579565.5 [Q68DK7-3] J3KTC2 Q68DK7 ENST00000577454.5 J3KSZ8 ENST00000578648.5 |